Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Related Citations for PubMed (Select 22221694)

1.

Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography.

Tanaka H, Iijima H, Nouso K, Aoki N, Iwai T, Takashima T, Sakai Y, Aizawa N, Iwata K, Ikeda N, Iwata Y, Enomoto H, Saito M, Imanishi H, Nishiguchi S.

Hepatol Res. 2012 Apr;42(4):376-84. doi: 10.1111/j.1872-034X.2011.00936.x. Epub 2012 Jan 3.

PMID:
22221694
3.

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.

Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, Jackson S, Ryder S, Price A, Stein K.

Health Technol Assess. 2007 Sep;11(34):1-206. Review.

4.

Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis.

Andersson KL, Salomon JA, Goldie SJ, Chung RT.

Clin Gastroenterol Hepatol. 2008 Dec;6(12):1418-24. doi: 10.1016/j.cgh.2008.08.005. Epub 2008 Aug 19.

5.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

6.

Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances.

Nouso K, Tanaka H, Uematsu S, Shiraga K, Okamoto R, Onishi H, Nakamura S, Kobayashi Y, Araki Y, Aoki N, Shiratori Y.

J Gastroenterol Hepatol. 2008 Mar;23(3):437-44. Epub 2007 Aug 6.

PMID:
17683496
7.

Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis.

Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U.

Clin Gastroenterol Hepatol. 2005 Jan;3(1):75-84.

PMID:
15645408
8.

Value of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma.

Goto E, Masuzaki R, Tateishi R, Kondo Y, Imamura J, Goto T, Ikeda H, Akahane M, Shiina S, Omata M, Yoshida H, Koike K.

J Gastroenterol. 2012 Apr;47(4):477-85. doi: 10.1007/s00535-011-0512-9. Epub 2011 Dec 27.

PMID:
22200940
9.

Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis.

Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, Ryder S, Cramp M, Stein K.

Br J Cancer. 2008 Apr 8;98(7):1166-75. doi: 10.1038/sj.bjc.6604301. Epub 2008 Apr 1.

10.

Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients.

Sangmala P, Chaikledkaew U, Tanwandee T, Pongchareonsuk P.

Asian Pac J Cancer Prev. 2014;15(20):8993-9004.

11.

Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis.

Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB.

Am J Gastroenterol. 2003 Mar;98(3):679-90.

PMID:
12650806
12.

Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population.

Cucchetti A, Trevisani F, Cescon M, Ercolani G, Farinati F, Poggio PD, Rapaccini G, Nolfo MA, Benvegn├╣ L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Pinna AD; Italian Liver Cancer (ITA.LI.CA) Group.

J Hepatol. 2012 May;56(5):1089-96. doi: 10.1016/j.jhep.2011.11.022. Epub 2012 Jan 13.

PMID:
22245900
13.

Usefulness of Sonazoid contrast-enhanced ultrasonography for hepatocellular carcinoma: comparison with pathological diagnosis and superparamagnetic iron oxide magnetic resonance images.

Korenaga K, Korenaga M, Furukawa M, Yamasaki T, Sakaida I.

J Gastroenterol. 2009;44(7):733-41. doi: 10.1007/s00535-009-0053-7. Epub 2009 Apr 23.

PMID:
19387532
14.

Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm.

Mita K, Kim SR, Kudo M, Imoto S, Nakajima T, Ando K, Fukuda K, Matsuoka T, Maekawa Y, Hayashi Y.

World J Gastroenterol. 2010 Sep 7;16(33):4187-92.

15.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

16.

Clinical translation in the treatment of hepatocellular carcinoma following the introduction of contrast-enhanced ultrasonography with Sonazoid.

Hiraoka A, Ichiryu M, Tazuya N, Ochi H, Tanabe A, Nakahara H, Hidaka S, Uehara T, Ichikawa S, Hasebe A, Miyamoto Y, Ninomiya T, Hirooka M, Abe M, Hiasa Y, Matsuura B, Onji M, Michitaka K.

Oncol Lett. 2010 Jan;1(1):57-61. Epub 2010 Jan 1.

17.

Contrast ultrasound in hepatocellular carcinoma at a tertiary liver center: First Indian experience.

Laroia ST, Bawa SS, Jain D, Mukund A, Sarin S.

World J Radiol. 2013 Jun 28;5(6):229-40. doi: 10.4329/wjr.v5.i6.229.

18.

Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK.

Canavan C, Eisenburg J, Meng L, Corey K, Hur C.

Dig Dis Sci. 2013 Sep;58(9):2691-704. doi: 10.1007/s10620-013-2705-y. Epub 2013 May 30.

19.

Utility of contrast-enhanced ultrasonography with Sonazoid in radiofrequency ablation for hepatocellular carcinoma.

Masuzaki R, Shiina S, Tateishi R, Yoshida H, Goto E, Sugioka Y, Kondo Y, Goto T, Ikeda H, Omata M, Koike K.

J Gastroenterol Hepatol. 2011 Apr;26(4):759-64. doi: 10.1111/j.1440-1746.2010.06559.x.

PMID:
21054516
20.

Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.

Lin OS, Keeffe EB, Sanders GD, Owens DK.

Aliment Pharmacol Ther. 2004 Jun 1;19(11):1159-72.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk